Shelter Pharma launches D3 cure capsules
This launch is part of the company's strategy to expand its nutraceutical portfolio
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The inspection concluded with one minor observation in Form 483
Subscribe To Our Newsletter & Stay Updated